Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Esperion (NASDAQ: ESPR) today and set a price target of $82. The company’s shares opened today at $49.22.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 9.3% and a 45.5% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Pieris Pharmaceuticals, Nektar Therapeutics, and United Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Esperion with a $85.63 average price target, representing a 74.0% upside. In a report issued on August 17, Citigroup also upgraded the stock to Buy with a $75 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $82.68 and a one-year low of $33.06. Currently, Esperion has an average volume of 760.7K.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ESPR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Esperion Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).
